AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05264155 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: GameBus (mHealth app)
Description: Using the mHealth app GameBus, participants could track their performance on 2 social leaderboards: a leaderboard displaying the individual scores of participants and a leaderboard displaying the average scores per department. To score points on these leaderboards, a participant was given a set of 6 tasks that, upon completion, were rewarded with points. In this study, 3/6 tasks were either updated generically (for the control group) or personalized (for the treatment group). By means of the mobile app, users could manually register that they had performed a task. Alternatively, users could use an activity tracker to automatically track their efforts. The activity trackers that were supported included Google Fit, Strava, and a GPS-based activity tracker. Finally, GameBus provided a set of features for social support: a newsfeed showed when other participants had scored points, and participants could like and comment on each other's healthy achievements as well as chat with each other.
Study NCT05264155 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GameBus (mHealth app)
Description: Using the mHealth app GameBus, participants could track their performance on 2 social leaderboards: a leaderboard displaying the individual scores of participants and a leaderboard displaying the average scores per department. To score points on these leaderboards, a participant was given a set of 6 tasks that, upon completion, were rewarded with points. In this study, 3/6 tasks were either updated generically (for the control group) or personalized (for the treatment group). By means of the mobile app, users could manually register that they had performed a task. Alternatively, users could use an activity tracker to automatically track their efforts. The activity trackers that were supported included Google Fit, Strava, and a GPS-based activity tracker. Finally, GameBus provided a set of features for social support: a newsfeed showed when other participants had scored points, and participants could like and comment on each other's healthy achievements as well as chat with each other.
Study NCT04018950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514
Description: intravenous infusion
Study NCT04018950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-ETX2514
Description: intravenous infusion
Study NCT03300479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevidipine
Description: Intravenous antihypertensive therapy with Clevidipine for the first 24 hours in patients with nontraumatic intracerebral hemorrhage (ICH).
Study NCT03300479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urapidil
Description: We compare the therapy with Urapidil to Clevidipine for the acute phase (24 hours) in patients with ICH. We would like to show the efficacy and safety of Clevidipine in this special situation.
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam
Study NCT04386616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSTT1041A
Description: Participants received one intravenous (IV) infusion of MSTT1041A 700 milligrams (mg) on Day 1. A second IV dose of MSTT1041A 350 mg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.
Study NCT00529542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipitor
Description: 40mg caplets per day for six weeks
Study NCT00529542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo caplet per day for six weeks.
Study NCT02838680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HLT Transcatheter Aortic Valve System
Description: Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
Study NCT00502177 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: QOL Questionnaires taking a total of 10 minutes to complete.
Study NCT04386616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MSTT1041A-matched Placebo
Description: Participants received up to 2 intravenous infusions of MSTT1041A-matched placebo.
Study NCT04386616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTTR1147A
Description: Participants received one intravenous (IV) infusion of UTTR1147A 90 micrograms/kilogram body weight (μg/kg) on Day 1. A second IV dose of UTTR1147A 90 μg/kg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.
Study NCT05454059 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal Examination
Description: All diagnostic procedures were performed with examination instruments (periodontal probe, dental mirror, x-ray device, etc.). Periodontal clinical index measurements (PI, GI, BOP, PPD, CAL) recorded from all teeth. Routine panoramic radiographs were taken from all patients to determine alveolar bone resorption. Vertical/horizontal bone losses on the radiographs were evaluated and used in the diagnosis of periodontitis.
Study NCT05454059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodontal Examination
Description: All diagnostic procedures were performed with examination instruments (periodontal probe, dental mirror, x-ray device, etc.). Periodontal clinical index measurements (PI, GI, BOP, PPD, CAL) recorded from all teeth. Routine panoramic radiographs were taken from all patients to determine alveolar bone resorption. Vertical/horizontal bone losses on the radiographs were evaluated and used in the diagnosis of periodontitis.
Study NCT03334279 — intervention group
Intervention type: OTHER
Intervention: Cigarette smokers
Description: frequent cigarette smoking for not less than 5 years
Study NCT03334279 — intervention group
Intervention type: OTHER
Intervention: Simultaneous cigarette and cannabis smokers
Description: frequent cigarette and cannabis smoking for not less than 5 years
Study NCT00267605 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FHPADHD
Description: Evidence-based psychological and behavioural distance intervention
Study NCT00267605 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ADHD Standard Care
Study NCT03114436 — intervention group
Intervention type: OTHER
Intervention: Observational Data Collection
Description: All aspects of deceased donor care in the ICU.
Study NCT03897946 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Birth dose hepatitis B vaccine
Description: Groups A and C will receive a birth dose of hepatitis B vaccine within 24 hours of life.
Study NCT01812356 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryomaze procedure using Nitrous oxide
Description: Cryomaze procedure using Nitrous oxide
Study NCT01812356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryomaze procedure using Argon
Description: Cryomaze procedure using Argon
Study NCT00541099 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Avastin 10.0 mg/kg on days 1 and 15
Study NCT00541099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Dexamethasone 4 mg evening before, morning of and evening of each dose of docetaxel.Docetaxel 35 mg/m2 on day 1, 8, 15
Study NCT03244319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: Patients who are randomly assigned to edoxaban group will be received 60mg qd or 30mg qd (creatinine clearance 30-49ml/min, body weight \<60kg or concomitant use of certain P-glycoprotein inhibitors).
Study NCT03244319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: All patients who are assigned to VKA group, bridging with warfarin and UFH is mandatory until INR reach therapeutic target range (INR 2-3). Warfarin dose will be adjusted for maintain therapeutic range (INR 2-3) during follow up period.
Study NCT03244319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: parenteral anti-coagulant (UFH)
Description: parenteral anti-coagulant (UFH)
Study NCT04386616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UTTR1147A-matched Placebo
Description: Participants received up to 2 intravenous infusions of UTTR1147A-matched placebo.
Study NCT00015873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Study NCT00015873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00015873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Study NCT00015873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT03184610 — intervention group
Intervention type: DEVICE
Intervention: OCT-scanning
Description: All participants will be scanned with a OCT-device
Study NCT00015873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Study NCT01952665 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
Study NCT01952665 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
Study NCT00015873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00631657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmirtazapine
Description: One esmirtazapine 4.5 mg tablet once a day
Study NCT01593423 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: plant-based Homestead Food Production
Description: The village model farm will be provided with the necessary inputs to establish their farm including saplings seeds etc.
Study NCT00631657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo tablet once a day
Study NCT01593423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Homestead Food Production plus small pond aquaculture
Description: In the case of the aquaculture arm a pond will be dug if there is not an existing pond and fingerlings and brood stocks will be provided. Hatcheries will be established if there is not one within a reasonable distance of the farms.
Study NCT01593423 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: a comparison group
Description: No intervention.
Study NCT04988711 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hb Oxymeter
Description: Measurement of Hb Oximeter
Study NCT01617135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-301
Study NCT01617135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01617135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinemet (carbidopa/levodopa)
Study NCT04254159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Superimposed Neuromuscular Electrical Stimulation
Description: NMES will be applied during each strengthening exercise session. A dual channel NMES stimulation device will be used with biphasic symmetric constant current impulses with a pulse width 300ms, a frequency of 50 Hz and a duty cycle of 10s on and 20s off protocol for 3 days a week for eight weeks.
Study NCT04254159 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quadriceps Strengthening
Description: Quadriceps strength training will be done with resistive elastics bands for 3 days a week for eight weeks.
Study NCT04254159 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education Program
Description: The aim of patient education is to increase awareness of patients about COPD and develop skills to better manage their disease. The patient education will be performed at least once via face to face interview. Education topics will be covered basic information about COPD, environmental risk factors, monitoring and managing the signs and symptoms of their disease, energy conservation techniques and relaxation positions to reduce dyspnea and usage of a specific inhaler.
Study NCT04254159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education Program
Description: The aim of patient education is to increase awareness of patients about COPD and develop skills to better manage their disease. The patient education will be performed at least once via face to face interview. Education topics will be covered basic information about COPD, environmental risk factors, monitoring and managing the signs and symptoms of their disease, energy conservation techniques and relaxation positions to reduce dyspnea and usage of a specific inhaler.
Study NCT04254159 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise Training
Description: Exercise training will be comprised of cardiovascular endurance training with cycle ergometer and lower extremity strength training. The exercises will be done 3 days a week at the clinic under the supervision of physiotherapist. Total duration of exercise training will last for 8 weeks
Study NCT04254159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: Exercise training will be comprised of cardiovascular endurance training with cycle ergometer and lower extremity strength training. The exercises will be done 3 days a week at the clinic under the supervision of physiotherapist. Total duration of exercise training will last for 8 weeks
Study NCT05945459 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-calorie density formula (1 kcal/ml)
Description: The dose is started from 20ml/kg/day divided into 8 feeds and increased by 20ml/kg/day until the feeding goal is reached (120-150ml/kg/day) during hospitalization. The intervention is then continued after discharge for 3 months (ad libitum).
Study NCT05945459 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Standard formula (0.67 kcal/ml)
Description: The dose is started from 20ml/kg/day divided into 8 feeds and increased by 20ml/kg/day until the feeding goal is reached (120-150ml/kg/day) during hospitalization. The intervention is then continued after discharge for 3 months (ad libitum).
Study NCT00666497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m2/day for 5 days, subcutaneous (SC) injection, Days 1 - 5 of every 28-day cycle
Study NCT00666497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD0103
Description: 90 mg, oral (PO) administration, 3 times per week for 12 doses, 28-day cycle
Study NCT00666497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD0103
Description: 90 mg, oral (PO) administration, 3 times per week for 10 doses, 28-day cycle
Study NCT00355342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 mcg BID
Description: Salmeterol xinafoate 50 mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.
Study NCT00355342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Salmeterol 250/50 mcg BID
Description: Fluticasone propionate/salmeterol xinafoate combination product 250/50mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.
Study NCT00355342 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISKUS inhaler
Description: Each participant received study medication via the DISKUS, for one of two possible treatment groups. Each DISKUS contained 60 doses of study medication. Participants were instructed to administer medication BID (one inhalation in the morning and one inhalation in the evening) approximately 12 hours apart for 156-week treatment period.
Study NCT02688582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TCI group
Description: Drug: cefepime, Device: Target Controlled Infusion pump connected to Rugloop vII software
Study NCT03659981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI 7T
Description: The imaging parameters will come from the 7 Tesla Siemens MRI
Study NCT02078609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGH447
Description: LGH447 in patients with AML or MDS
Study NCT02078609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGH447 + midostaurin
Description: LGH447 + midostaurin in patients with AML
Study NCT03978585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high tone external muscle stimulation
Description: Participants receive self-administered home based high tone therapy for 8 weeks for 30 minutes daily after device instruction
Study NCT03978585 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high tone external muscle stimulation
Description: Participants receive self-administered home based high tone therapy for 8 weeks for 30 minutes daily after device instruction
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam
Study NCT05454059 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saliva Sample Collection
Description: Saliva samples were collected from all subjects in the morning. Unstimulated saliva from each patient was collected by standard defined spitting method without stimulation.
Study NCT05454059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva Sample Collection
Description: Saliva samples were collected from all subjects in the morning. Unstimulated saliva from each patient was collected by standard defined spitting method without stimulation.
Study NCT03978585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical nerve stimulation (TENS) therapy
Description: Participants receive self-administered home based TENS therapy for 8 weeks for 30 minutes daily after device instruction
Study NCT03978585 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous electrical nerve stimulation (TENS) therapy
Description: Participants receive self-administered home based TENS therapy for 8 weeks for 30 minutes daily after device instruction
Study NCT02775734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl-cysteine
Description: N-acetyl-cysteine + Clomiphene citrate + Laparoscopic ovarian drilling
Study NCT02775734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate
Description: Clomiphene citrate + Laparoscopic ovarian drilling
Study NCT01396460 — intervention group
Intervention type: OTHER
Intervention: breakfast (a chicken sandwich with juice)
Description: patients received a breakfast after de initial measurement
Study NCT05482009 — intervention group
Intervention type: OTHER
Intervention: Traditional Chinese Medicine Treatment Combined with Western Medicine Basic Treatment
Description: The cumulative observation and treatment (including Chinese patent medicine, Chinese medicine decoction, Chinese medicine granule, Chinese medicine injection, and western medicine) were more than 5 months, and the follow-up was 1.5 years.
Study NCT01782664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg GSK2586184
Description: 100 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
Study NCT01782664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg GSK2586184
Description: 200 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
Study NCT01782664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg GSK2586184
Description: 400 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
Study NCT01782664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets to be taken twice daily with food for up to 84 days.
Study NCT00776347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Dosage: 3mg PO/day for the first 2 weeks and 5mg PO/day for the next 14 weeks Duration: 16 weeks
Study NCT00776347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Study NCT04062838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 50
Description: As above
Study NCT04111679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Participant selected music, applied using noise cancelling headphones
Study NCT01082965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 5 mg tablets once daily for 7 days and then 10mg on 8th day
Study NCT01082965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT02056912 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Amplification by PCR and direct sequencing on the entire coding sequence and intron-exons boundaries of the candidate gene
Study NCT02056912 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Perform blood cells and fibroblasts biochemical and immuno-labeled investigations
Description: Performed only in the two index patients enrolled in the sub-study
Study NCT05892367 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Transbrachial Access for Interventions
Description: Adding a positioning splint in addition to compression bandage after intervention in order to guarantee immobilization of puncture site
Study NCT05892367 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transbrachial Access for Interventions
Description: Adding a positioning splint in addition to compression bandage after intervention in order to guarantee immobilization of puncture site